Baseline prostatic specific antigen does not predict the outcome of high energy transurethral microwave thermotherapy

Journal of Urology

Volumn 167, Issue 4 I, 2002, Pages 1727-1730

  Laguna, M Pilar ^a   Kiemeney, Lambertus A ^a   Debruyne, Frans M J ^a   De La Rosette, Jean J M C H ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Hyperthermia, induced; Outcome assessment (health care); Prostate; Prostate specific antigen; Questionnaires

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; DEVICE; HUMAN; HYPERTHERMIC THERAPY; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MICROWAVE IRRADIATION; MINIMALLY INVASIVE SURGERY; OUTCOMES RESEARCH; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROSTATE DISEASE; QUALITY OF LIFE; RECEIVER OPERATING CHARACTERISTIC; RESIDUAL VOLUME; URINE VOLUME; UROFLOWMETRY;

EID: 0036130381     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0022-5347(05)65187-7     Document Type: Article

References (18)

1. Clinical efficacy of a new 30-min algorithm for transurethral microwave thermotherapy: Initial results
2. Prospective randomized comparison of high energy transurethral microwave thermotherapy versus alpha-blocker treatment of patients with benign prostatic hyperplasia
3. A high-efficiency microwave thermoablation system for the treatment of benign prostatic hyperplasia: Results of a randomized, sham-controlled, prospective, double-blind, multicenter clinical trial
4. The predictive value of baseline variables in the treatment of benign prostatic hyperplasia using high-energy transurethral microwave thermotherapy
5. Responders and non-responders to treatment of benign prostatic hyperplasia with transurethral microwave thermotherapy
6. Responders and nonresponders to transurethral microwave thermotherapy: A multicenter retrospective analysis
7. Serum prostate-specific antigen and prostate volume predict long-term changes in symptoms and flow rate: Results of a four-year, randomized trial comparing finasteride versus placebo
8. Pretreatment prostate-specific antigen as an outcome predictor of targeted transurethral microwave thermotherapy
9. Clinical research criteria
10. Transurethral thermotherapy
11. Benign prostatic hyperplasia specific health status measures in clinical research: How much change in the American Urological Association Symptom Index and the benign prostatic hyperplasia impact index is perceptible to patients?
12. The ICS-'BPH' study: Uroflowmetry, lower urinary tract symptoms and bladder outlet obstruction
13. How to select patients for high-energy transurethral microwave thermotherapy
14. Transurethral microwave thermotherapy for benign prostatic hyperplasia: Relation between clinical response and prostate histology
15. Can histopathology predict treatment outcome following high-energy transurethral microwave thermotherapy of the prostate. Results of a biopsy study
16. Pressure/flow study analyses in patients treated with high-energy thermotherapy (Prostasoft 2.5)
17. Transurethral microwave thermotherapy of benign prostatic hyperplasia: Do any pretreatment conditions predict the result?
18. Serum prostate-specific antigen as a predictor of prostate volume in men with benign prostatic hyperplasia